Silvia Hernández-Llodrà

Prof. Silvia Hernández-Llodrà


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Laboratory Investigation
Verified
Journal Article
Closed access
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
SMSilvia de Muga
Silvia de Muga
LALaia Agell
Laia Agell
NJNuria Juanpere
Nuria Juanpere
RERaquel Esgueva
Raquel Esgueva
JLJosep Lloreta
Josep Lloreta

5 March 2010 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
SMSilvia de Muga
Silvia de Muga
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
LALaia Agell
Laia Agell
MSMarta Salido
Marta Salido
NJNuria Juanpere
Nuria Juanpere
JLJosep Lloreta
Josep Lloreta
Prostate cancer is the second cause of cancer-related death in men of the Western world. The potential prognostic role of the combined alterations in EGFR and PTEN in prostate cancer is not well established. It was the aim of the study to investigate this role. Prevalence of EGFR and PTEN somatic mutations, EGFR amplification and EGFR protein expression were investigated in a series of prostate adenocarcinomas, classified according to the current Gleason grading system. Mutational analysis revealed eight EGFR and three PTEN mutations in 98 (8%) and 92 (3%) prostate adenocarcinomas, respectively. The combined prevalence of EGFR–PTEN mutations was 11%. EGFR overexpression was present in 31% of adenocarcinomas, with a marginally significant difference (P=0.068) between Gleason grade ≤7 adenocarcinomas and Gleason grade ≥8 and metastatic adenocarcinomas. Four cases (4 of 31; 13%) had an EGFR gene gain due to chromosome 7 polysomy. In 35% of adenocarcinomas we found some type of EGFR–PTEN alteration, with a tendency to be associated with advanced-stage prostate adenocarcinomas (P=0.04). The IVS18+19 polymorphism was also associated with more advanced prostate adenocarcinomas. This is the first study reporting mutations of EGFR and PTEN in the same series of prostate adenocarcinomas. Protein overexpression is the most frequent EGFR abnormality. Mutations in EGFR and PTEN genes are a minor event, although prostate cancer represents the third neoplasm in which the EGFR gene mutations are more prevalent. Alterations in the EGFR–PTEN signaling pathway are present in a third of prostate adenocarcinomas, particularly affecting the more advanced cases.

4 May 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
AFAlba Font‐Tello
Alba Font‐Tello
NJNúria Juanpere
Núria Juanpere
SMSilvia de Muga
Silvia de Muga
MLMarta Lorenzo
Marta Lorenzo
JLJose Antonio Lorente
Jose Antonio Lorente
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà

1 January 2006 in Ultrastructural Pathology
Verified
Journal Article
Closed access
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
JLJosep Lloreta
Josep Lloreta
Molecular studies on whole samples of fresh or frozen tissue do not take into account the heterogeneity of these tissues. In addition to normal cells, precursor lesions and different progression stages may be mixed within a given sample. Usually, the dominant cell population will determine the results and may sometimes mask biologically relevant abnormalities. To obtain more specific information and knowledge on changes within different cell compartments, many techniques have been developed that combine morphological observation and selection with different strategies for specific cell dissection. In this review, the most important micro-dissection methods are put into perspective, and some requirements and limitations are discussed with regard to sample fixation, staining, dissection and molecular analysis.

17 June 2019 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
RARaquel Albero-González
Raquel Albero-González
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
NJNuria Juanpere
Nuria Juanpere
MLMarta Lorenzo
Marta Lorenzo
ALAdrià Lloret
Adrià Lloret
JLJosep Lloreta-Trull
Josep Lloreta-Trull

1 April 2017 in Human Pathology
Verified
Journal Article
Closed access
JLJosep Lloreta
Josep Lloreta
AFAlba Font-Tello
Alba Font-Tello
NJNúria Juanpere
Núria Juanpere
AFAlbert Frances
Albert Frances
MLMarta Lorenzo
Marta Lorenzo
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà